BioNTech submitting applications in US and Europe for vaccine to be available to those aged 12-15
BioNTech’s Covid-19 vaccine, jointly developed with Pfizer, should be available to 12- to 15-year-olds in Europe from June, the chief executive of the German company has said.
Uğur Şahin said BioNTech had submitted its application for emergency approval of vaccines for this age group in the US at the start of April, and next Wednesday would be ready to submit the application for approval by the European Medicines Agency.
